X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in patients with worsening ischemic heart failure. HiCM-188 electrically couple with the patient's myocardium to generate contractile force (remuscularization).
Lead Product(s): HiCM-188
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HiCM-188
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
The financing will help the company conduct and complete clinical trials of its fully independent intellectual property development pipeline, iPSC heart cell injection, and will initiate clinical studies of immune cell therapy based on iPSC technology within the next year.
Lead Product(s): iPSC-derived Cardiomyocyte
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ming Bioventures
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
